A new warning is coming to every GLP-1 label, and it is about your eyes
I have been on Zepbound for almost two years, so I read this one the way you probably did: first the worry, then the questions. Here is the news, and then the part that actually matters, which is what to watch for.
On Monday, November 9, the FDA told every maker of a GLP-1 drug to add a new warning to its label. The warning is about a rare eye condition called NAION, and it will go in the Warnings and Precautions section of the label for every GLP-1: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, and the rest of the class.
What NAION is, in plain words
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain words, it is a stroke of the optic nerve, the cable that carries pictures from your eye to your brain. Blood flow to the front of the nerve drops, and vision in one eye goes, usually suddenly and usually without pain.
It is the most common cause of sudden optic nerve damage in people over 50. There is no treatment that undoes the damage, which is why getting seen the same day matters so much.
What the FDA actually found
The FDA looked at 126 clinical trials covering 134,253 patients. Across all of them, there were 15 probable NAION events: 10 in people taking a GLP-1 and 5 in people taking a placebo. That works out to about 6.4 cases per 100,000 person-years on a GLP-1, versus 3.8 on a comparator.
Read that carefully, because the numbers are small and the FDA's own wording is careful. The agency calls it a "potential increased risk." It did not say these drugs cause NAION. Its review of animal data found no mechanism for how a GLP-1 would raise the risk, and the studies behind the signal do not all point the same way. This is not a recall, and the FDA has not told anyone to stop their medication on their own.
How rare is rare? In the general population over 50, NAION happens in roughly 2 to 10 people per 100,000 each year. Europe's regulator, which acted on semaglutide first in June 2025, estimates about one extra case per 10,000 person-years of treatment.
And the eye doctors' own groups, the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society, reviewed more than 40 studies in May 2026 and concluded the relative risk for semaglutide may be about doubled, which still means a small absolute increase, because the starting number is so low.
They do not recommend routine eye exams just to check NAION risk before starting one of these drugs.
What to watch for when taking GLP-1s
NAION usually hits one eye; it usually does not hurt, and people often notice it first thing in the morning when they wake up. Get seen the same day by an eye doctor or in the emergency room if you notice any of these:
Sudden loss of vision in one eye, even if it does not hurt
A new dark patch, shadow, or blind spot
The top or bottom half of your view looking dim or missing
Blurred or dim vision in one eye
Colors looking washed out in one eye
Do not wait to see if it clears up, and do not stop your medication on your own. Europe's regulator says the drug should be stopped if NAION is confirmed, and that is a decision for your doctor, made with an eye specialist.
How this eye warning got here
The concern started with a 2024 study from doctors at Mass Eye and Ear, published in JAMA Ophthalmology, who noticed three NAION cases in a single week, all in people taking semaglutide.
Europe's safety committee reviewed the evidence and, in June 2025, called NAION a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. The UK followed in February 2026. Now the FDA has acted, and its warning covers the whole class, not just semaglutide.
The bottom line
This is a real warning about a real but rare condition, and it belongs on the label. It is not a reason to panic, and it is not a reason to stop a drug that is working for you without talking to your prescriber.
It is a reason to know the symptoms, because with NAION, hours matter and there is no do-over for the nerve. If your vision changes suddenly in one eye, get seen that day.
Report any eye issues or other serious side effects to the MedWatch Voluntary Reporting Form if you feel comfortable doing so.
Comments